July 26, 2022
Life Sciences
  • A federal appeals court in New York upheld a lower-court ruling against Pfizer Inc. that said the drugmaker’s Direct Copay Assistance Program violated an anti-kickback law. The federal government had argued that Pfizer’s financial support for reimbursable drugs would result in Medicare having to cover “astronomical” drug prices. Pfizer said in a statement that the program represented a “fair and effective way to lower out-of-pocket costs and help ensure affordable access” – to heart medicines Vyndaqel and Vyndamax.” (Article here)